TY - GEN
T1 - Oligonuleotide delivery with dendritic poly(L-lysine) for treatments of the liver disorders
AU - Watanabe, K.
AU - Harada-Shiba, M.
AU - Suzuki, A.
AU - Higuchi, Y.
AU - Kawakami, S.
AU - Hashida, M.
AU - Gokuden, R.
AU - Kurihara, R.
AU - Sugao, Y.
AU - Mori, T.
AU - Katayama, Y.
AU - Niidome, T.
PY - 2010
Y1 - 2010
N2 - A cationic peptide dendrier, dendritic poly(L-lysine), forms complexes with oligonucleotides and can deliver them to liver after intravenous injection. Here, we tried to deliver apolipoprotein B-specific siRNA for the treatment of hypercholesterolemia and NFκB decoy for the hepatitis treatment. Significant therapeutic effects in those disease model mice were observed after intravenous injection of the oligonucleotides complexes with dendritic poly(L-lysine).
AB - A cationic peptide dendrier, dendritic poly(L-lysine), forms complexes with oligonucleotides and can deliver them to liver after intravenous injection. Here, we tried to deliver apolipoprotein B-specific siRNA for the treatment of hypercholesterolemia and NFκB decoy for the hepatitis treatment. Significant therapeutic effects in those disease model mice were observed after intravenous injection of the oligonucleotides complexes with dendritic poly(L-lysine).
UR - http://www.scopus.com/inward/record.url?scp=79951995179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951995179&partnerID=8YFLogxK
M3 - Conference contribution
AN - SCOPUS:79951995179
SN - 9781617822155
T3 - Materials Research Society Symposium Proceedings
SP - 12
EP - 17
BT - Nanobiotechnology and Nanobiophotonics - Opportunities and Challenges
T2 - 2009 MRS Fall Meeting
Y2 - 30 November 2009 through 2 December 2009
ER -
